Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years Su-Hyun Kim, MD; Woojun Kim, MD, PhD; Xue Feng Li, MD, MSc; In-Ja Jung, RN; Ho Jin Kim, MD, PhD Arch Neurol. ?2011;68(11):1412-1420. doi:10.1001/archneurol.2011.154 Objective? To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO).
Dian He a , c , Qizhu Wu b , Xiuying Chen a , Daidi Zhao a , Qiyong Gong b and Hongyu Zhou a , , a Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China b Department of Radiology, Huaxi MR Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China c Department of Neurology, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou Province, China Accepted 27 May 2011.? Available online 1 July 2011. ? Abstract The objective of this study investigated cognitive impairments and their correlations with fractional anisotropy (FA) and mean diffusivity (MD) in patients with neuromyelitis optica (NMO) without visible lesions on conventional brain MRI during acute relapse.
Varieties of autoantibodies are known to relate to autoimmune neurological disorders as the diagnostic and therapeutic markers. Some of them affected directly to the pathomechanisms of neurological diseases
OBJECTIVE: To evaluate the efficacy and safety of repeated rituximab treatment based on the assessment of peripheral circulating memory B cells over 24 months in patients with relapsing neuromyelitis optica (NMO). DESIGN: Prospective open-label study.
The status of fatigue, depression, and activities of daily living and their relationships with cognitive function in patients with neuromyelitis optica (NMO) after acute relapse has never been observed. This study investigated cognitive function, fatigue, depression, activities of daily living, and the relationships among them in NMO patients. Twenty-two NMO patients without visible lesions on conventional brain MRI after acute relapse, 22 depression patients, and 22 healthy comparison subjects received several scales to assess cognitive function, fatigue, and depression